Education
About Us
Working with TipRanks
Follow Us
Viatris, Inc. (DE:VIA)
:VIA
VIA Stock Chart & Stats
€9.43
€0.08(0.69%)
At close: 4:00 PM EST
€9.43
€0.08(0.69%)
Day’s Range― - ―
52-Week Range€6.28 - €12.43
Previous CloseN/A
Volume947.00
Average Volume (3M)7.44K
Market Cap
€10.80B
Enterprise Value€25.14B
Total Cash (Recent Filing)€1.11B
Total Debt (Recent Filing)€14.72B
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Mar 02, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.58
Shares Outstanding1,151,769,900
10 Day Avg. Volume2,719
30 Day Avg. Volume7,439
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.80
Price to Sales (P/S)1.01
P/FCF Ratio7.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.02Price Target Upside6.20% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Leadership And Strategic DirectionThe company is undergoing a positive transformation under a refreshed leadership team, supported by a market-leading branded portfolio, a progressive generics foothold, and a robust pipeline with blockbuster potential.
Market Position And Growth PotentialThe company's transition into a reputable global specialty pharma with a generics and branded base business supports leverage for new product additions.
Strategic PlanningThe nearing completion of 'Phase 1' strategic plan includes stabilizing the base business, growing the pipeline, and reducing debt, indicating a solid path for future growth.
Bears Say
Manufacturing And Compliance IssuesThe company is facing a manufacturing overhang at its Indore, India facility after receiving a Warning Letter and a US Import Ban on 11 products due to poor quality controls and inadequate handling of manufacturing errors.
Potential Impact On Other FacilitiesThe manufacturing issues at the Indore facility pose a potential risk of spillover to other facilities, raising concerns over broader operational impacts.
Regulatory And Litigation RisksThere are risks including regulation and pricing uncertainty, litigation, and regulatory scrutiny of manufacturing compliance that could impact the company's operations.
Viatris News
VIA FAQ
What was Viatris, Inc.’s price range in the past 12 months?
Viatris, Inc. lowest stock price was €6.28 and its highest was €12.43 in the past 12 months.
What is Viatris, Inc.’s market cap?
Viatris, Inc.’s market cap is €10.80B.
When is Viatris, Inc.’s upcoming earnings report date?
Viatris, Inc.’s upcoming earnings report date is Mar 02, 2026 which is in 84 days.
How were Viatris, Inc.’s earnings last quarter?
Viatris, Inc. released its earnings results on Nov 06, 2025. The company reported €0.575 earnings per share for the quarter, beating the consensus estimate of €0.533 by €0.042.
Is Viatris, Inc. overvalued?
According to Wall Street analysts Viatris, Inc.’s price is currently Undervalued.
Does Viatris, Inc. pay dividends?
Viatris, Inc. does not currently pay dividends.
What is Viatris, Inc.’s EPS estimate?
Viatris, Inc.’s EPS estimate is 0.46.
How many shares outstanding does Viatris, Inc. have?
Viatris, Inc. has 1,151,769,900 shares outstanding.
What happened to Viatris, Inc.’s price movement after its last earnings report?
Viatris, Inc. reported an EPS of €0.575 in its last earnings report, beating expectations of €0.533. Following the earnings report the stock price went down -4.116%.
Which hedge fund is a major shareholder of Viatris, Inc.?
Currently, no hedge funds are holding shares in DE:VIA
Viatris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€10.02 (6.20% Upside)
€10.02 (6.20% Upside)
Blogger Sentiment
Neutral
DE:VIA Sentiment 50%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.89%
12-Months-Change
Fundamentals
Return on Equity
-21.09%
Trailing 12-Months
Asset Growth
-15.27%
Trailing 12-Months
Company Description
Viatris, Inc.
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
VIA Company Deck
VIA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of strong commercial performance in certain segments and strategic advancements in R&D, offset by challenges related to the Indore facility and specific market declines. The company is actively addressing these issues and making progress in its strategic initiatives.View all DE:VIA earnings summariesVIA Net sales Breakdown
62.62% Brands
37.38% Generics
VIA Stock 12 Month Forecast
Average Price Target
€10.02
▲(6.20% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Options Prices
Currently, No data available
---